...the ESMO Congress will feature two poster presentations and an ePoster with additional clinical and health-related quality of life data from the TAPISTRY clinical trial in patients with RET fusion-positive thyroid cancer... (Rigel Press Release) - Oct 19, 2026 - "In the TAPISTRY clinical trial cohort that evaluated pralsetinib in 16 response-evaluable thyroid cancer patients with RET fusion-positive tumors, pralsetinib demonstrated robust and durable activity against RET fusion-positive thyroid cancer with an ORR of 81.3% and manageable safety, results that are consistent with the ARROW study and further highlight its utility in this population."
P2 data • Thyroid Gland Carcinoma
|